Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New therapy on the horizon for ALK+ non-small cell lung cancer

04.06.2012
A new compound that targets anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer is well-tolerated by patients and is already showing early signs of activity, including in patients who no longer respond to crizotinib—the only approved ALK inhibitor.

Results of this Novartis-sponsored sudy will be presented by a researcher from Fox Chase Cancer Center during the 2012 Annual Meeting of the American Society of Clinical Oncology on Sunday, June 3.

The compound LDK378, developed by Novartis, targets ALK—a key cancer gene in a subset of lung cancer, lymphoma and the childhood cancer neuroblastoma, and may be associated with other cancers, including breast and colorectal cancer. The study's authors looked at patients with ALK+ lung cancer, as well as other ALK+ solid tumors. Early data from the phase I study show that the majority of patients treated with active doses of LDK378 responded, including those who had progressed after treatment with crizotinib.

"These results are encouraging," says study author Ranee Mehra, M.D., assistant professor and medical oncologist at Fox Chase. "They offer hope to patients who have tumors with alterations involving ALK, even if they have relapsed from previous treatments.

In its first test in people, designed to determine the compound's safety and optimal dose, 56 people with various types of ALK+ solid tumors (primarily lung cancer) were enrolled, receiving doses between 50 to 750 milligrams per day (mg/day). LDK378 was well-tolerated in most patients up to 750 mg/d, with the most common side effects being nausea, vomiting, and diarrhea.

"Whenever you do a trial with a drug, even if it's just designed to look for safety and dosage, you are interested in whether patients responded," says Mehra. "These results are definitely encouraging, and mean we can go forward with additional research looking at whether LDK378 is effective in various types of cancers that have alterations involving ALK."

The fact that patients appeared to tolerate LDK378 at doses up to 750 mg/d is also encouraging, she adds, since preclinical research has suggested this dose would have therapeutic effects.

In the meantime, Mehra and investigators at other centers around the world are continuing to enroll patients in the trial. The next phase of the study will test the maximum tolerated dose of LDK378 in all patients enrolled.

This study was sponsored and funded by Novartis.

Mehra's co-authors include: Mehra's co-authors include: [D. Ross Camidge (University of Colorado, Denver, CO), Sunil Sharma (Huntsman Cancer Center, Salt Lake City, UT), Enriqueta Felip (Vall d'Hebron University Hospital, Barcelona, Spain), Daniel Shao-Weng Tan (National Cancer Centre, Singapore, Singapore), Johan F. Vansteenkiste (University Hospital Gasthuisberg, Leuven, Belgium), Tommaso Martino De Pas (European Institute of Oncology, Milan, Italy), Dong-Wan Kim (Seoul National University Hospital, Seoul, South Korea), Armando Santoro (Humanitas Cancer Center, Rozzano, Italy), Geoffrey Liu (Princess Margaret Hospital, Toronto, ON), Meredith Goldwasser (Novartis Institutes for BioMedical Research, Cambridge, MA), David Dai (Novartis Pharmaceuticals, East Hanover, NJ), Marietta Radona (Novartis Pharmaceuticals, East Hanover, NJ), Anthony Boral (Novartis Institutes for BioMedical Research, Cambridge, MA), Alice Tsang Shaw (Massachusetts General Hospital Cancer Center, Boston, MA).

Fox Chase Cancer Center is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence three consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, visit Fox Chase's Web site at www.foxchase.org or call 1-888-FOX CHASE or (1-888-369-2427).

Diana Quattrone | EurekAlert!
Further information:
http://www.fccc.edu

Further reports about: ALK ALK+ Cancer LDK378 Nobel Prize Novartis Oncology Pharmaceuticals clinical research lung cancer

More articles from Health and Medicine:

nachricht A new approach to targeting cancer cells
20.05.2019 | University of California - Riverside

nachricht Radioisotope couple for tumor diagnosis and therapy
14.05.2019 | Kanazawa University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Self-repairing batteries

UTokyo engineers develop a way to create high-capacity long-life batteries

Engineers at the University of Tokyo continually pioneer new ways to improve battery technology. Professor Atsuo Yamada and his team recently developed a...

Im Focus: Quantum Cloud Computing with Self-Check

With a quantum coprocessor in the cloud, physicists from Innsbruck, Austria, open the door to the simulation of previously unsolvable problems in chemistry, materials research or high-energy physics. The research groups led by Rainer Blatt and Peter Zoller report in the journal Nature how they simulated particle physics phenomena on 20 quantum bits and how the quantum simulator self-verified the result for the first time.

Many scientists are currently working on investigating how quantum advantage can be exploited on hardware already available today. Three years ago, physicists...

Im Focus: Accelerating quantum technologies with materials processing at the atomic scale

'Quantum technologies' utilise the unique phenomena of quantum superposition and entanglement to encode and process information, with potentially profound benefits to a wide range of information technologies from communications to sensing and computing.

However a major challenge in developing these technologies is that the quantum phenomena are very fragile, and only a handful of physical systems have been...

Im Focus: A step towards probabilistic computing

Working group led by physicist Professor Ulrich Nowak at the University of Konstanz, in collaboration with a team of physicists from Johannes Gutenberg University Mainz, demonstrates how skyrmions can be used for the computer concepts of the future

When it comes to performing a calculation destined to arrive at an exact result, humans are hopelessly inferior to the computer. In other areas, humans are...

Im Focus: Recording embryonic development

Scientists develop a molecular recording tool that enables in vivo lineage tracing of embryonic cells

The beginning of new life starts with a fascinating process: A single cell gives rise to progenitor cells that eventually differentiate into the three germ...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

 
Latest News

Cement as a climate killer: Using industrial residues to produce carbon neutral alternatives

20.05.2019 | Materials Sciences

When bees are freezing

20.05.2019 | Life Sciences

Machine learning speeds modeling of experiments aimed at capturing fusion energy on Earth

20.05.2019 | Power and Electrical Engineering

VideoLinks
Science & Research
Overview of more VideoLinks >>>